Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation vs BCG for High-risk NMIBC
NCT06324058Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2025
01
Overview
Randomised, open-label trial (2 arms), sponsored by Huashan Hospital. Primary endpoint: Tumor residual rate. Planned start Mar 2024; status: not yet recruiting.
Beyond the preview
Go deeper on NCT06324058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06324058.